Stefano Volinia1, Gerard Nuovo2, Alessandra Drusco2, Stefan Costinean2, Ramzey Abujarour2, Caroline Desponts2, Michela Garofalo2, Raffaele Baffa2, Rami Aeqilan2, Kati Maharry2, Maria Elena Sana2, Maria Elena Sana Ramiro Garzon2, Gianpiero Di Leva2, Pierluigi Gasparini2, Paola Dama2, Jlenia Marchesini2, Marco Galasso2, Marco Manfrini2, Carlotta Zerbinati2, Fabio Corrà2, Timothy Wise2, Sylwia E Wojcik2, Maurizio Previati2, Flavia Pichiorri2, Nicola Zanesi2, Hansjuerg Alder2, Jeff Palatini2, Kay F Huebner2, Charles L Shapiro2, Massimo Negrini2, Andrea Vecchione2, Anne L Rosenberg2, Carlo M Croce2, Ramiro Garzon2. 1. Department of Molecular Virology, Immunology and Molecular Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH (SV, GN, AD, SC, MiG, RAe, RG, GDL, PG, PD, TW, SEW, FP, NZ, HA, KFH, CMC); Biosystems Analysis, LTTA, Deptartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy, (SV, MES, JM, MaG, MM, CZ, FC, MP, JP, MN); Fate Therapeutics, San Diego, CA (RAb); Department of Chemistry, The Scripps Research Institute, La Jolla, CA (CD); Department of Urology, Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, PA (RB); Comprehensive Cancer Center, The Ohio State University, Columbus, OH (KM); Deptartment of Internal Medicine, James Cancer Hospital and Ohio State University Comprehensive Cancer Center, The Ohio State University (CLS); Division of Pathology, II University of Rome "La Sapienza," Ospedale Santo Andrea, Rome, Italy (AV); Department of Surgery, Thomas Jefferson University Medical College, Philadelphia, PA (ALR). carlo.croce@osumc.edu. 2. Department of Molecular Virology, Immunology and Molecular Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH (SV, GN, AD, SC, MiG, RAe, RG, GDL, PG, PD, TW, SEW, FP, NZ, HA, KFH, CMC); Biosystems Analysis, LTTA, Deptartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy, (SV, MES, JM, MaG, MM, CZ, FC, MP, JP, MN); Fate Therapeutics, San Diego, CA (RAb); Department of Chemistry, The Scripps Research Institute, La Jolla, CA (CD); Department of Urology, Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, PA (RB); Comprehensive Cancer Center, The Ohio State University, Columbus, OH (KM); Deptartment of Internal Medicine, James Cancer Hospital and Ohio State University Comprehensive Cancer Center, The Ohio State University (CLS); Division of Pathology, II University of Rome "La Sapienza," Ospedale Santo Andrea, Rome, Italy (AV); Department of Surgery, Thomas Jefferson University Medical College, Philadelphia, PA (ALR).
Abstract
BACKGROUND: The purpose of this study is to determine whether microRNA for pluripotent stem cells are also expressed in breast cancer and are associated with metastasis and outcome. METHODS: We studied global microRNA profiles during differentiation of human embryonic stem cells (n =26) and in breast cancer patients (n = 33) and human cell lines (n = 35). Using in situ hybridization, we then investigated MIR302 expression in 318 untreated breast cancer patients (test cohort, n = 22 and validation cohort, n = 296). In parallel, using next-generation sequencing data from breast cancer patients (n = 684), we assessed microRNA association with stem cell markers. All statistical tests were two-sided. RESULTS: In healthy tissues, the MIR302 (high)/MIR203 (low) asymmetry was exclusive for pluripotent stem cells. MIR302 was expressed in a small population of cancer cells within invasive ductal carcinoma, but not in normal breast (P < .001). Furthermore, MIR302 was expressed in the tumor cells together with stem cell markers, such as CD44 and BMI1. Conversely, MIR203 expression in 684 breast tumors negatively correlated with CD44 (Spearman correlation, Rho = -0.08, P = .04) and BMI1 (Rho = -0.11, P = .004), but positively correlated with differentiation marker CD24 (Rho = 0.15, P < .001). Primary tumors with lymph node metastasis had cancer cells showing scattered expression of MIR302 and widespread repression of MIR203. Finally, overall survival was statistically significantly shorter in patients with MIR302-positive cancer cells (P = .03). CONCLUSIONS: In healthy tissues the MIR302(high)/MIR203(low) asymmetry was characteristic of embryonic and induced pluripotency. In invasive ductal carcinoma, the MIR302/MIR203 asymmetry was associated with stem cell markers, metastasis, and shorter survival.
BACKGROUND: The purpose of this study is to determine whether microRNA for pluripotent stem cells are also expressed in breast cancer and are associated with metastasis and outcome. METHODS: We studied global microRNA profiles during differentiation of human embryonic stem cells (n =26) and in breast cancerpatients (n = 33) and human cell lines (n = 35). Using in situ hybridization, we then investigated MIR302 expression in 318 untreated breast cancerpatients (test cohort, n = 22 and validation cohort, n = 296). In parallel, using next-generation sequencing data from breast cancerpatients (n = 684), we assessed microRNA association with stem cell markers. All statistical tests were two-sided. RESULTS: In healthy tissues, the MIR302 (high)/MIR203 (low) asymmetry was exclusive for pluripotent stem cells. MIR302 was expressed in a small population of cancer cells within invasive ductal carcinoma, but not in normal breast (P < .001). Furthermore, MIR302 was expressed in the tumor cells together with stem cell markers, such as CD44 and BMI1. Conversely, MIR203 expression in 684 breast tumors negatively correlated with CD44 (Spearman correlation, Rho = -0.08, P = .04) and BMI1 (Rho = -0.11, P = .004), but positively correlated with differentiation marker CD24 (Rho = 0.15, P < .001). Primary tumors with lymph node metastasis had cancer cells showing scattered expression of MIR302 and widespread repression of MIR203. Finally, overall survival was statistically significantly shorter in patients with MIR302-positive cancer cells (P = .03). CONCLUSIONS: In healthy tissues the MIR302(high)/MIR203(low) asymmetry was characteristic of embryonic and induced pluripotency. In invasive ductal carcinoma, the MIR302/MIR203 asymmetry was associated with stem cell markers, metastasis, and shorter survival.
Authors: Suling Liu; Gabriela Dontu; Ilia D Mantle; Shivani Patel; Nam-shik Ahn; Kyle W Jackson; Prerna Suri; Max S Wicha Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701
Authors: Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall Journal: Nat Cell Biol Date: 2008-03-30 Impact factor: 28.824
Authors: Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Michail Shipitsin; Lauren L Campbell; Pedram Argani; Stanislawa Weremowicz; Noga Bloushtain-Qimron; Jun Yao; Tatiana Nikolskaya; Tatiana Serebryiskaya; Rameen Beroukhim; Min Hu; Marc K Halushka; Saraswati Sukumar; Leroy M Parker; Karen S Anderson; Lyndsay N Harris; Judy E Garber; Andrea L Richardson; Stuart J Schnitt; Yuri Nikolsky; Rebecca S Gelman; Kornelia Polyak Journal: Cancer Cell Date: 2007-03 Impact factor: 31.743
Authors: Carol Sheridan; Hiromitsu Kishimoto; Robyn K Fuchs; Sanjana Mehrotra; Poornima Bhat-Nakshatri; Charles H Turner; Robert Goulet; Sunil Badve; Harikrishna Nakshatri Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Joseph H Taube; Gabriel G Malouf; Emily Lu; Nathalie Sphyris; Vidya Vijay; Priyanka P Ramachandran; Katumasa R Ueno; Sanchaika Gaur; Milena S Nicoloso; Simona Rossi; Jason I Herschkowitz; Jeffrey M Rosen; Jean-Pierre J Issa; George A Calin; Jeffrey T Chang; Sendurai A Mani Journal: Sci Rep Date: 2013 Impact factor: 4.379
Authors: Nadia P Castro; Natalie D Fedorova-Abrams; Anand S Merchant; Maria Cristina Rangel; Tadahiro Nagaoka; Hideaki Karasawa; Malgorzata Klauzinska; Stephen M Hewitt; Kajal Biswas; Shyam K Sharan; David S Salomon Journal: Oncotarget Date: 2015-05-20